AllRock Bio raised $50 million to advance ROC-101, an oral therapy for pulmonary hypertension (PH) and related lung diseases. The drug works by relaxing blood vessels, reducing inflammation, and preventing tissue scarring, offering a potential new option for patients with these serious rare conditions.
